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Systematic proﬁlingIn order to investigate the global and dynamic host microRNAs (miRNAs)/messenger RNAs (mRNAs)
expression alteration during in vitro acute HCV infection, a comprehensive microarray analysis was
performed using human hepatoma cells. Totally, 108 human miRNAs and 1247 mRNAs were identiﬁed
whose expression levels changed for more than 2.0-fold in response to HCV infection. Upon HCV infection,
signature from the unique miRNA expression pattern reﬂected the involvement of miRNA-regulated host
cellular physiology and antiviral mechanism, whereas a preponderance of differentially regulated genes
associated with metabolism, cell growth, apoptosis and cytokine/chemokine pathways. Furthermore, a
reverse regulatory association of differentially expressed miRNAs and their predicted targets was
constructed. Finally, the differentially expressed miRNAs such as miR-24, miR-149⁎, miR-638 and miR-
1181 were identiﬁed to be involved in HCV entry, replication and propagation. These results suggest that
combined miRNA and mRNA proﬁling may have superior potential as a diagnostic and mechanistic feature in
HCV infection.
© 2009 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV) is a major human blood-borne pathogen
that has infected almost 170 million people worldwide and induces
hepatic cirrhosis and hepatocellular carcinomas (HCC) (Choo et al.,
1989; Shepard et al., 2005). Our understanding of the dynamic host
response to HCV infection had been greatly hampered until the JFH-1-
derived cell culture-grown HCV (HCVcc) system became available in
2005 (Cai et al., 2005; Lindenbach et al., 2005; Wakita et al., 2005;
Zhong et al., 2005). This new HCVcc system now permits us to study
the entire virus life cycle in vitro and to devise strategies for
prophylactic and therapeutic interventions.
Up to date, JFH-1 or JFH-1-derived chimeras have been success-
fully utilized in studies such as co-receptor identiﬁcation and virus
transmission (Evans et al., 2007; Liu et al., 2009; Timpe et al., 2008),
immune and chemokine pathways (Johansson et al., 2007; Uzri and
Gehrke, 2009; Ye et al., 2009), fatty acid synthesis (Yang et al., 2008a),
rRNA transcription (Raychaudhuri et al., 2009), lipid metabolism
(Amemiya et al., 2008) and apoptosis (Zhu et al., 2007). Increasing
evidence has demonstrated that microRNAs (miRNAs) have profound
impact in modulating HCV infection and host defense (Jopling et al.,.
ll rights reserved.2005; Pedersen et al., 2007). Similar to small interference RNA
(siRNA), miRNAs are small, endogenous non-coding RNAs that
assemble into RISC complexes, guide them onto target transcripts
and then bind mRNAs at their 3′ untranslated regions (UTR) and
ultimately induce mRNA degradation or suppress protein translation
(Bartel, 2004). Many miRNAs are regulated in response to cellular
stress including infections and are known to modify essential cellular
functions of antiviral effects, cell proliferation, differentiation and
apoptosis (Marsit et al., 2006). For example, a recent study has
implicated the liver-speciﬁc miR-122 as an essential regulator of HCV
replication in cultured human hepatoma cell Huh7 (Jopling et al.,
2005). Moreover, another study of chronic hepatitis C liver biopsies
demonstrated that the miR-122 level was markedly lower in primary
nonresponding subjects than in early virological responding subjects
regardless of the HCV genotype examined (Sarasin-Filipowicz et al.,
2009). Furthermore, researchers recently discovered that interferon
beta (IFNβ) rapidly modulated host miRNAs, of which ﬁve showed
signiﬁcant anti-HCV effects in a viral sequence-speciﬁc manner
(Pedersen et al., 2007). Above evidence suggests a critical role of
host miRNAs in regulating HCV infection.
Although the miRNA expression proﬁle was investigated recently
in HCC to reveal the mechanisms of liver oncogenic progress
(Varnholt et al., 2008), the dynamic and global changes of miRNA
expressions in HCVcc-infected cell culture model has yet to be
extensively elucidated. In this study, we performed comprehensive
Fig. 1. qRT-PCR conﬁrmation of randomly selected miRNAs and mRNAs from
microarray. Expression comparison of randomly selected 5 miRNAs (A) and 5 genes
(B) from microarray data was performed using quantitative real-time RT-PCR. Results
were shown in fold change pattern of HCVUV/HCV.
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roles of several identiﬁed miRNAs were subsequently examined for
their capabilities to regulate HCV infection and replication.
Results
HCV infection alters host miRNA expression in hepatoma cells
To proﬁle global changes in miRNAs, naïve Huh7.5.1 cells were
inoculated with relative high titer (MOI=1.0) JFH-1 virus or same
amount of UV-inactivated virus (HCVUV) at day 0 for overnight and
then washed and allowed for further culture for 1, 2, 3 and 4 days,
respectively, before total RNA preparation. Virus infection at various
time points was conﬁrmed by immunoﬂuorescent staining of the cells
with antibody against HCV structure protein Core. The percentage of
Core-positive cells increased gradually over the course of infection,
while the HCVUV-infected cells showed completely negative staining
at all times (Supplemental Fig. 1A). To monitor the possible virus
infection-caused cytotoxicity, the MTT assay was carried out. Upon
inoculation of Huh7.5.1 cells with HCV or HCVUV, no signiﬁcant cell
death was observed except for a ∼20% cell viability reduction in
HCVcc-infected cells on the fourth day (Supplemental Fig. 1B).
Together, we were able to establish a dynamic in vitro HCV infection
system for further global gene expression proﬁling.
Subsequently, we examined the hepatocytes miRNA proﬁles in
response to acute HCV infection with the CapitalBio multi-species
miRNA microarray (version 4.0; for details, see Materials and
methods), on which triplicate probes were included. After the
ﬁltration of the signals below the threshold level, 142 miRNAs
(including human, non-human and predicted miRNAs) were identi-
ﬁed as differentially expressed N2.0-fold in HCVcc-infected samples
(Supplemental Tables 1–4). To conﬁrm the microarray hybridization
results, RT-qPCR was performed on ﬁve randomly selected differen-
tially expressed miRNAs. All the selected miRNAs exhibited expres-
sional patterns that are consistent with the microarray results
(Fig. 1A), indicating the reliability of themicroarraydata. Unsupervised
clustering (Fig. 2A) and scatter (Supplemental Fig. 2) analysis of the
expression proﬁles revealed a distinct miRNA signature during acute
HCV infection and demonstrated that the majority of the differentially
expressedmiRNAswere up-regulated in response to virus infection. In
summary, 5 miRNAs from day 1 sample, 40 miRNAs from day 2, 63
miRNAs from day 3 and 108 miRNAs from day 4 were differentially
expressed by more than two-fold after infection. In addition to day 1,
the intersection of the number of co-regulatedmiRNAs on day 2, 3 and
4 are illustrated in Fig. 2B. The result suggests a continuous and well-
regulated miRNA expression pattern through the course of infection.
The most signiﬁcant 22 up-regulated and 20 down-regulated miRNAs
in response to HCV exposure are summarized in Table 1, in which
8 down-regulated and10up-regulatedmiRNAswith thehighest fold of
change (Figs. 2C and D) were selected for further functional study.
mRNA expression proﬁle of HCV-infected hepatoma cells
A 35K human genome array was used to perform a comprehensive
analysis of mRNA expression from HCV or HCVUV-infected Huh7.5.1
cells, on which we also had the miRNA expression proﬁles. Of 25,100
genes represented on the array, 1247 genes were differentially
expressed N2.0-fold (with P-value b0.01, estimated false discovery
rate 0.03) during various time courses between infected and control
cells (Supplemental Tables 5–8). Unlike the miRNA proﬁle, the
clustering result demonstrated that the number of up-regulated and
down-regulated mRNAs are almost identical between HCV-infected
and control cells (Fig. 3A). Quantitative RT-PCR conﬁrmation on
randomly selected differentially expressed mRNAs from microarrays
demonstrated a satisfying consistence (Fig. 1B). The overlaps of co-
regulated genes on day 2, 3 and 4 showed similar pattern with miRNAproﬁle (Fig. 3B), and the co-regulated genes among all the 3 days are
summarized in Table 2. These consistently co-regulated genes may
play critical roles in infection-induced cytopathogenesis and virus
replication itself. Similarly, the top 25 up- and 25 down-regulated
genes and their average fold of change during 4 days are showed in
Figs. 3C and D. To elucidate the correlation between gene expression
pattern and HCV infection-induced biological processes, functional
classiﬁcation of mRNA transcripts by Gene Ontology terms and
pathway analysis were performed (Fig. 4). Upon in vitroHCV infection
of hepatoma cells, serine protease inhibitor family members (SERPIN-
C1, D1, F2), chemokines (CCL20, CXCL5), TGF-β superfamily members
(BMP2, GDF15) and various tRNA synthetases (CARS, MARS, WARS
etc.) may play central roles for HCV pathogenesis (Fig. 4B).
Correlation of miR and mRNA expression alteration during HCV infection
To determine whether miRNAs might be modulators of those
mRNAs that were differentially expressed, we investigated whether
those differentially expressed mRNAs are enriched for predicted
targets of each of the human miRNAs in MSigDb database (http://
www.broad.mit.edu/gsea/msigdb/annotate.jsp), in which gene sets
contain genes sharing a 3′-UTR miRNA binding motif. To our surprise,
targets for the top 10 miRNA or miRNA families account for 17% of the
differentially expressedmRNAs in HCV-infected hepatocytes, whereas
targets for the top 20 account for 23%, and top 50 for 31% of the
differentially expressed mRNAs. Seventeen HCV-affected miRNAs or
miRNA families with at lease 4 HCV-affected mRNA targets are listed
in Supplementary Table 9. Although the total number ofmiRNAs listed
in MSigDB is only 222, far less than the miRNA probes represented on
themicroarray, this preliminary analysis still support the notion that a
relatively small number of miRNAs alteration in response to HCV
infection could potentially contribute to a large number of changes in
mRNA expression. Modulation of speciﬁc miRNAs might represent a
Fig. 2. miRNA expression in HCV-infected hepatocytes. (A) Unsupervised hierarchical clustering of differentially expressed miRNAs in HCV-infected Huh7.5.1 cells at different
infection time points. Red indicates higher expression and green indicates lower expression in HCV-infected cells. Black means no expression difference; gray indicates signals under
detection level. The small ﬁgure represents color scales used in the cluster map. (B) Overlaps of co-regulated miRNAs (N2.0-fold) across various infection time courses. Data from day
1 was omitted. Eight down-regulated (C) and 10 up-regulated (D) miRNAs with the highest expression difference (Pb0.01) in HCV-infected Huh7.5.1 cells are demonstrated.
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propagation. To this end, we compared the reverse correlation for
some of the differentially expressed miRNAs with some of their
putative mRNA targets. With the use of either the PicTar or the
Targetscan databases, results in Table 3 demonstrated that many
differentially expressed miRNAs were inversely correlated with their
predicted targets.
Potential effects of differentially expressed miRNAs on HCV entry,
replication and propagation
MiRNA could exert regulatory effects on both host and the
pathogen. To further investigate whether HCV life cycle is potentiallyaffected by the selected miRNAs, 8 mimics for down-regulated
miRNAs and 10 inhibitors for up-regulated miRNAs were synthesized,
transfected into cells. Virus entry assay demonstrated that over-
expression of hsa-miR-923 or inhibition of hsa-miR-149⁎, 373⁎, 638,
888, 940, 1181, 1234 slightly increased HCVpp entry (∼1.4- to
1.6-fold) (Fig. 5A). By contrast, none of the miRNA mimics or
inhibitors suppressed virus entry. When using genotype 1b replica-
tion system, gain of miR-221, 455-3p and loss of miR-887, 940
expression enhanced, but gain of miR-24 and loss of miR-149⁎, 373⁎
expression suppressed HCV RNA abundance (Fig. 5B). Finally, HCVcc
system was assessed. Results in Fig. 5C demonstrated that transfec-
tions of a fewmiRNAmimics or inhibitors into JFH1-infected Huh7.5.1
cells indeed altered HCV RNA abundance.
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Almost 30% of protein-coding genes are predicted to be regulated
by miRNAs. Currently, nearly a thousand human miRNAs have been
experimentally or in silica cloned, with each of them potentially
regulating hundreds of genes by complementary binding to the 3′-
UTR of target mRNAs. A number of miRNAs have been shown to play
important roles in tumorigenesis, developmental timing and cell
death as well as pathogen infection. The liver-speciﬁc miR-122 is the
ﬁrst host miRNA that exerts a positive effect on HCV replication in cell
culture by binding in the viral 5′-UTR (Jopling et al., 2005). Recent
report further demonstrated that the in vivo steady level of miR-122
correlates with the hepatitis C responsiveness to Interferon therapy
(Sarasin-Filipowicz et al., 2009). Moreover, several interferon-
modulated cellular miRNAs were characterized to target HCV genome
and show signiﬁcant antiviral effects in a sequence-speciﬁc manner
(Pedersen et al., 2007). Collectively, these ﬁndings highlight the
important role of host miRNAs in regulating the liver-speciﬁc HCV
replication, and suggest that miRNAs might be potential targets for
hepatitis C therapy. For that reason, the systematic discovery of
miRNAs involved in HCV life cycle is urgently needed. Recently,Table 1
List of top differentially expressed miRNAs of hepatocytes in response to HCV acute infectio
microRNA HCVUV/HCVcc (mean)
1D 2D 3D
Up-regulated
hsa-miR-888 0.2262 UD 0.10435
hsa-miR-940 UD UD 0.107
hsa-miR-149⁎ 0.76985 0.9603 0.19395
hsa-miR-1181 UD 0.66655 0.0819
hsa-miR-486-3p UD UD UD
hsa-miR-638 0.9198 0.96025 0.16065
hsa-miR-92b⁎ UD UD 0.2298
hsa-miR-1246 UD UD 0.17975
hsa-miR-373⁎ UD UD 0.12125
hsa-miR-663 UD 1.0001 0.1069
hsa-miR-1908 0.83315 0.73085 0.16485
hsa-miR-1914⁎ UD UD 0.16145
hsa-miR-1228⁎ 1.0193 UD 0.22815
hsa-miR-365 UD UD UD
hsa-miR-1469 UD UD 0.1297
hsa-miR-1915 UD UD 0.27235
hsa-miR-30c-1⁎ UD UD UD
hsa-miR-491-5p UD 0.3943 0.238
hsa-miR-1290 UD UD UD
hsa-miR-675 UD 0.80215 0.1605
hsa-miR-1913 UD 0.18725 UD
hsa-miR-187⁎ UD UD UD
Down-regulated
hsa-miR-18b 1.1149 UD 1.9325
hsa-miR-107 1.34205 0.3951 UD
hsa-miR-15a 1.08065 0.2441 1.8799
hsa-miR-181a 1.67335 3.96905 2.41205
hsa-miR-30c UD UD 2.1891
hsa-miR-130a 1.4615 UD 1.91365
hsa-miR-106b 1.4583 UD 2.28845
hsa-miR-221 UD UD 3.1364
hsa-miR-93 1.2671 UD 2.3475
hsa-miR-24 1.6991 1.30595 2.5707
hsa-miR-18a 1.3149 UD 2.39025
hsa-miR-1201 UD 0.46245 2.7384
hsa-miR-29a 1.2034 0.5192 2.5445
hsa-miR-151-3p UD 2.34315 3.0507
hsa-miR-26a 1.4445 0.3561 2.40945
hsa-miR-664 UD UD 5.44245
hsa-miR-301b UD UD 3.23955
hsa-miR-455-5p UD UD 3.45375
hsa-miR-455-3p UD UD 13.59225
hsa-miR-210 UD 9.717 4.6329
UD indicates undetected.several studies reported the global miRNAmodulation in HCV or HCC-
related liver biopsy samples (Peng et al., 2009; Ura et al., 2009;
Varnholt et al., 2008) as well as the identiﬁcation of 188 candidate
miRNA expression modiﬁcation in JFH-1 RNA transfected cells (Ura
et al., 2009). However, the dynamic and high-throughput miRNA
proﬁling during in vitro HCV acute infection and the potential
functional signiﬁcance of the differentially expressed miRNAs on
HCV life cycle are still left unknown.
In this study, based on a comprehensive examination of miRNA
expression from JFH-1 HCV-infected and parallel UV-inactivated
virus-infected hepatocytes, we identiﬁed 142 miRNAs that are
differentially expressed, with most (60%) up-regulated in HCV-
infected cells. This ﬁnding is not similar to prior miRNAs study in
HCV-associated HCC (Varnholt et al., 2008), in which 60% differen-
tially expressed miRNAs were down-regulated. Also, only 4 miRNAs
(miR-15a, miR-16, miR-106a and miR-199b) are overlapped between
two studies. This may be because miRNA response in acute infection
cell model is tightly linked to cell stress or survival and different from
that in chronic infection and cancer that are more relevant to
differentiation, ﬁbrosis and tumorigenesis. Recent reports docu-
mented that host miRNAs (miR-122, miR-199a⁎, miR-196, miR-296,n.
Chromosome location Potential targets
4D
0.00975 Xq27.3 NFAT5,NFYB
0.03245 16P13.3 PDS5A, SSH2
0.0337 2q37.7 AAK1, PHLPPL
0.0355 19p13.2 NEUROD2,H1FX
0.03645 8p11.21 FJL14154,RGAG4
0.038 19p13.2 STARD10, NPAS4
0.04415 1q22 P13, ARHGAP8
0.0462 2q31.1 FAM53C,CREBL2
0.0479 19q13.41 CROT, ZKSCAN1(373)
0.04915 20p11.21 GRIN2D,HSPG2
0.05015 11q12.2 Unknown
0.05765 20q13.3 Unknown
0.06635 12q13.3 Unknown
0.0744 16p13.12 LPAR5,NRIB
0.0763 15q26.2 Unknown
0.07645 10p12.31 Unknown
0.07865 1p34.2 TREX2,HGS
0.0806 9p21.3 GATAD2B,FOXP4
0.086 1p36.13 EHHADH,RTKN2
0.089 11p15.5 CALN1, MARK4
0.09045 6q27 Unknown
0.0953 18q12.2 ANKMY1, TRPC4
3.24375 Xq26.2 NEDD9,GLRB
3.32925 10q23.31 DICER1,TMEM16C
3.42875 13q14.3 AFF4,E2F3
3.4518 1q31.3/9q33.3 AFF4,DDX3X
3.47325 1p34.2/6q13 E2F3,MMD
3.58475 11q12.1 ACSL1,CLCN5
3.79565 7q22.1 JUB,EIF4G2
4.18645 Xp11.3 HRB,EIF3S1
4.4694 7q22.1 MAPK9,KLHL18
4.70065 9q22.32/19p13.12 AMOTL2,CCT3
4.76715 13q31.3 NEDD9,GLRB
4.95205 14q11.2 SAMD12,AAK1
5.95215 7q32.3 TRAF4,RND3
6.00525 8q24.3 RGS6,UPP2
6.17725 3p22.2/12q14.1 CHORDC1,POLR3G
6.7645 1q41 HS6ST3,AHCTF1
9.4938 22q11.21 MIER1,SLAIN1
13.52905 9q32 PPP1R12A,GDAP2
43.88985 9q32 NFIB,BRWD1
45.1445 11p15.5 ISCU,GIT2
Fig. 3. mRNA expression in HCV-infected hepatocytes. (A) Unsupervised hierarchical clustering of differentially expressed mRNAs in HCV-infected Huh7.5.1 cells at different
infection time points. Red indicates higher expression and green indicates lower expression in HCV-infected cells versus control. Black indicates no expression difference. (B)
Overlaps of co-regulated mRNAs (N2.0-fold) across various infection time courses. Data from day 1 was omitted. The 25 most up-regulated (C) and 25 most down-regulated (D)
mRNAs in HCV-infected Huh7.5.1 cells are shown in average fold change across all 4 infection days.
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replication by targeting viral genome (Jopling et al., 2005; Murakami
et al., 2009; Pedersen et al., 2007). Thus, we analyzed whether these
miRNAs are differentially expressed in response to virus infection as
well. Interestingly, upon HCV acute infection in hepatocytes, miR-122
was down-regulated (2.8-fold), whereas miR-296 (4.9-fold) andmiR-
351 (15.2-fold) were up-regulated signiﬁcantly at day 4 post-
infection. Such results suggest a host defense response is perhaps
mounted to elevate the levels of those antiviral miRNAs and suppress
those are supportive to virus infection. This might be also caused by
the indirect effects of HCV-induced interferon production.
Because we are unclear how many differentially expressed
miRNAs in this study are truly regulators of HCV infection, 18 miRNAs
with the highest expression variation and without any previous clue
to HCV infection were selected for further functional study, in which
8 miRNAs are down-regulated and 10 up-regulated (Fig. 5). Several
tested miRNAs indeed showed regulatory effects on HCV entry or
replication, although results obtained from three experimental
systems are hardly consistent. Especially, the lack of concordance of
the effects of miRNAs between replicon system and HCVcc system is
unexpected (Figs. 5B and C). On one hand, this may be explained by
the characteristics of multiple targets of individual miRNA and thesedifferent gene targets exert distinct biological function on HCVcc life
cycle. On the other hand, different genotypes, adaptive mutations,
with or without an entry step between HCVcc and replicon systems
might all potentially make those differences. In general, results from
Fig. 5 suggest us that host miRNAs could be efﬁcient therapeutic
targets for HCV infection by modulating their expression. Here we
take miR-24 for instance, it belongs to miR-23b cluster that targets
Smads and suppresses TGF-β/BMP signaling in liver cells (Rogler
et al., 2009). In this study, miR-24 was down-regulated post-HCV
infection (Table 1), and we calculated the fold change of the
intracellular HCV RNA abundance is ∼2-fold decreased after the
transfection of miR-24 mimic into HCVcc-infected Huh7.5.1 cells
(Fig. 5B). These results suggest that host TGF-β signal pathwaymight
be potentially activated upon HCV infection and thereafter a liver
ﬁbrosis progress was accelerated. Thus, systematic administration of
miR-24 might not only decrease virus replication level but also
inhibit hepatic ﬁbrosis.
Several methods and studies have been established to address the
regulatory relationships between miRNA and mRNA expression (Hon
and Zhang, 2007; Marcucci et al., 2008). Our simultaneous collecting
miRNA and mRNA data from the same samples allowed unveiling
correlations of two sets expression proﬁle and their potential
Table 2
List of most consistently modiﬁed genes of hepatocytes in response to HCV acute infection.
Gene symbol Gene name HCVUV/HCVcc (mean) Molecular function Cellular component
1D 2D 3D 4D
Up-regulated
POPDC2 Popeye domain containing 2 0.0189 0.083 0.0794 0.0866 Unknown Membrane; integral to
membrane;
GDF15 Growth differentiation factor 15 0.605 0.0977 0.0601 0.0658 Cytokine activity; growth factor activity Extracellular space
NR0B2 Nuclear receptor subfamily 0,
group B, member 2
0.5356 0.1903 0.1504 0.2712 Transcription corepressor activity; steroid hormone
receptor activity; transcription factor activity
Nucleus
ATF3 Activating transcription factor 3 0.873 0.14 0.0681 0.0674 Sequence-speciﬁc DNA binding; transcription corepressor
activity; protein dimerization activity; transcription factor
activity
Nucleus
TNFRSF12A Tumor necrosis factor receptor
superfamily, member 12A
0.5961 0.3159 0.1509 0.2217 Protein binding; receptor activity Membrane; integral to
membrane
LARP6 La ribonucleoprotein domain
family, member 6
0.1035 0.4878 0.3878 0.3633 RNA binding; nucleotide binding Cytoplasm; nucleus;
ribonucleoprotein
complex
S100P S100 calcium binding protein P 0.711 0.2976 0.1297 0.2045 Magnesium ion binding; calcium-dependent protein
binding; calcium ion binding
Cytoplasm; nucleus
CCL20 Chemokine (C-C motif) ligand 20 0.6872 0.3037 0.1598 0.261 Chemokine activity Extracellular space
GADD45A Growth arrest and DNA-damage-
inducible, alpha
0.9292 0.2692 0.1776 0.1808 Unknown Nucleus
MTHFD2 Methylenetetrahydrofolate
dehydrogenase (NADP+
dependent) 2,
methenyltetrahydrofolate
cyclohydrolase
1.1215 0.2254 0.1257 0.1206 Hydrolase activity; methylenetetrahydrofolate
dehydrogenase (NADP+) activity; oxidoreductase activity;
magnesium ion binding; methylenetetrahydrofolate
dehydrogenase (NAD+) activity; phosphate binding;
methenyltetrahydrofolate cyclohydrolase activity
Mitochondrion
CTH Cystathionase (cystathionine
gamma-lyase)
0.85 0.2407 0.2955 0.2733 Cystathionine gamma-lyase activity; lyase activity Unknown
RND3 Rho family GTPase 3 1.2063 0.2058 0.1855 0.088 Nucleotide binding; GTP binding Golgi stack;
intracellular
ID1 Inhibitor of DNA binding 1,
dominant-negative helix–loop–
helix protein
1.2371 0.4633 0.8375 0.9334 Protein binding; transcriptional repressor activity Nucleus
JUN jun oncogene 1.0542 0.1612 0.1988 0.3727 RNA polymerase II transcription factor activity; sequence-
speciﬁc DNA binding; protein dimerization activity;
transcription factor activity; transcription factor binding
Nuclear chromosome
DNAJB9 DnaJ (Hsp40) homolog, subfamily
B, member 9
1.0705 0.3515 0.189 0.2561 Chaperone regulator activity; unfolded protein binding;
heat shock protein binding
Nucleolus; cytoplasm;
nucleus
SQSTM1 Sequestosome 1 1.1484 0.3813 0.2433 0.1389 Ubiquitin binding; metal ion binding; SH2 domain binding;
protein kinase binding; zinc ion binding
Cytosol; nucleus
SLC3A2 Solute carrier family 3 (activators
of dibasic and neutral amino acid
transport), member 2
1.0499 0.5901 0.1981 0.11 Calcium:sodium antiporter activity; alpha-amylase activity Cell surface;
membrane; integral to
membrane
KLF6 Kruppel-like factor 6 1.1845 0.3343 0.1756 0.2575 Metal ion binding; zinc ion binding; DNA binding;
transcriptional activator activity
Nucleus
SLC7A5 Solute carrier family 7 (cationic
amino acid transporter, y+
system), member 5
1.1196 0.5201 0.2184 0.1145 Amino acid permease activity; neutral amino acid
transporter activity
Plasma membrane;
integral to membrane
HERPUD1 Homocysteine-inducible,
endoplasmic reticulum
stress-inducible, ubiquitin-like
domain member 1
1.0333 0.4744 0.2692 0.3896 Unknown Endoplasmic reticulum
membrane; membrane;
integral to membrane
TRIB3 Tribbles homolog 3 (Drosophila) 1.4303 0.2994 0.1254 0.1423 Protein kinase inhibitor activity; ATP binding; protein
binding; protein kinase binding; protein kinase activity;
transcription corepressor activity
Nucleus
Down-regulated
HDHD3 Haloacid dehalogenase-like
hydrolase domain containing 3
1.7177 7.1833 15.8024 1.9188 Hydrolase activity; phosphoglycolate phosphatase activity Unknown
RGS14 Regulator of G-protein
signaling 14
4.0125 2.6803 4.8661 12.9926 Receptor signaling protein activity; GTPase activator
activity
Unknown
EIF4H Eukaryotic translation initiation
factor 4H
1.6982 1.5803 15.4493 1.257 Translation initiation factor activity; RNA binding;
nucleotide binding
Eukaryotic translation
initiation factor 4F
complex
ARG1 Arginase, liver 1.0522 1.378 1.5378 15.3488 Extracellular matrix structural constituent; cysteine-type
endopeptidase activity
Extracellular region
ELOF1 Elongation factor 1 homolog
(S. cerevisiae)
1.2793 6.7626 6.5184 2.3069 Metal ion binding; zinc ion binding Nucleus
ATAD1 ATPase family, AAA domain
containing 1
1.5024 0.8722 13.5673 0.6332 ATP binding; nucleotide binding; nucleoside-
triphosphatase activity
Unknown
EPHX1 Epoxide hydrolase 1, microsomal
(xenobiotic)
1.209 2.5857 10.2859 1.6187 Hydrolase activity; epoxide hydrolase activity Endoplasmic reticulum;
microsome;
membrane; integral to
membrane
TMCC1 Transmembrane and coiled coil
domains 1
0.8573 1.1731 1.4995 11.6291 Unknown Membrane; integral to
membrane
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Table 2 (continued)
Gene symbol Gene name HCVUV/HCVcc (mean) Molecular function Cellular component
1D 2D 3D 4D
EPO Erythropoietin 1.271 1.3359 1.444 11.0151 Hormone activity; erythropoietin receptor binding Extracellular space
KIF22 Kinesin family member 22 0.9736 10.7807 1.5804 1.3917 ATP binding; nucleotide binding; microtubule motor
activity; sequence-speciﬁc DNA binding
Microtubule associated
complex; kinetochore;
nucleus; microtubule
CPB2 Carboxypeptidase B2 (plasma) 1.5843 2.1498 2.9224 7.5 Metal ion binding; zinc ion binding; metallopeptidase
activity; carboxypeptidase activity; carboxypeptidase A
activity
Unknown
GPX7 Glutathione peroxidase 7 3.8581 7.3974 1.6027 1.0054 Oxidoreductase activity; glutathione peroxidase activity Unknown
TTC14 Tetratricopeptide repeat
domain 14
1.2936 9.5299 1.8073 0.889 RNA binding; Unknown
FARS2 Phenylalanyl-tRNA synthetase 2,
mitochondrial
6.474 1.0593 3.332 2.5128 Phenylalanine-tRNA ligase activity; ATP binding; tRNA
binding; ligase activity; nucleotide binding
Soluble fraction;
mitochondrion
PCOLCE Procollagen C-endopeptidase
enhancer
2.7612 1.8774 3.2183 4.9729 Collagen binding Unknown
63X. Liu et al. / Virology 398 (2010) 57–67regulatory network during HCV infection. Within the top 10
differentially expressed miRNAs that correlate with differentially
expressed mRNAs discovered in this study (Table 3), several of them
have been implicated in other diseases and biological process. For
instance, miRNAs encoded by the miR-15/16 cluster are known to be
involved in apoptosis (Cimmino et al., 2005; Guo et al., 2009), Nodal
signaling (Martello et al., 2007) and tumorigenesis (Bonci et al.,
2008). miRNAs encoded by the miR-17/miR-106b cluster are
important for epithelial morphogenesis (Carraro et al., 2009),
hepatocellular carcinoma (Li et al., 2009) and transforming growth
factor beta signaling (Petrocca et al., 2008). miR-29a/b are involved in
host-HIV-1 interaction (Nathans et al., 2009), p53 pathway (Park
et al., 2009) and skeletal myogenesis (Wang et al., 2008). These
ﬁndings suggest that the expression modiﬁcation of host miRNAs
during acute HCV infection could be related to a number of cellular
physiological processes that eventually control the cell fate after
combating with virus.
In this study, obtaining mRNA expression proﬁle together with
miRNA proﬁling cannot only provide a systematic data for miRNA
regulatory network construction but also implicate the more accurate
biological signiﬁcance for HCV acute infection based on our existing
knowledge. Recently, Walters and colleagues (2009) reported J6/JFH
chimeric HCV infection-induced hepatocytes mRNA proﬁling using
similar strategy, and suggested the potential regulation of cell cycle
and apoptosis-related genes. By comparing these two sets data of
mRNA proﬁling, a signiﬁcant coherence was observed. Among 42
differentially expressed genes identiﬁed in this study across 2–4 days
post-infection, total 32 (76%) of them were also reported to be
regulated in Walters' study (data not shown). The consistent results
from two independent experiments suggest the conserved HCV
infection-stimulated cellular responses and cytopathic mechanisms
existed. After carefully analyzing those differentially expressed
mRNAs, we are interested in a number of genes that may deserve
for further characterization. Among them, the expression of several
circulating factors, including lipoprotein metabolism components
(APOA1, APOC1, APOC2, APOC3, APOH, APOM), bone morphogenetic
protein 2 (BMP2), erythropoietin (EPO), transforming growth factor,
beta-induced (TGFBI) and growth and differentiation factor 15
(GDF15), was signiﬁcantly regulated, which suggests that these
factors might be prognostic biomarkers and dysregulate host
homeostasis after HCV infection. The notable suppression of tight
junction protein Claudin-14 (CLDN14) after infection implicated the
potential role of CLDN14 on HCV entry (Evans et al., 2007; Yang et al.,
2008b). The mechanisms of chronic hepatitis C-related hepatocellular
carcinoma are still under debating between pathogen and immuno-
logical stress-induced tumorigenesis. Interestingly, our mRNA proﬁl-
ing results demonstrated that among differentially expressed genes,
all 7 oncogenes (MYC, DEK, ELF3, JAK1, KLF6, KRAS and PTPN11) were
up-regulated, but the only tumor suppressor fumarate hydratase (FH)was down-regulated. This result provided evidence that virus
propagation stimulated liver genemodiﬁcationmight exert important
function on HCV-induced hepatocarcinogenesis.
In summary, these ﬁndings suggest that host miRNAs are an
important category of targets and may play a role in regulating the
gene expression response to HCV infection in liver cells. miRNA and
mRNA proﬁles obtained from these cells might therefore serve as
biomarkers for HCV-related liver diseases and help elucidate the
regulatory mechanisms that mediate the host response to HCV
exposure and other pathogens.
Materials and methods
Cells, HCVcc production and infection
The human hepatoma cell line Huh7.5.1 was provided by Dr.
Francis V. Chisari (The Scripps Research Institute, La Jolla, CA). The
HCV genotype 1b-replicon-containing cell line (2−3+) was a
generous gift from Dr. Stanley Lemon (University of Texas Medical
Branch, Galveston, TX). HEK293T cells were obtained from ATCC. All
cell lines were maintained in DMEM (Gibco/Invitrogen, Carlsbad, CA)
supplemented with 1% Penicillin and streptomycin (Gibco), 1% NEAA
(Gibco) and 10% fetal bovine serum (Gibco) in a 37 °C 5% CO2
atmosphere. G418 (500 μg/ml) was routinely added into the 2–3+
cells to maintain the viral RNA replication. The production of HCVcc
(JFH-1) was performed as described (Wakita et al., 2005). Brieﬂy, JFH-
1 genome RNA was in vitro transcribed with RiboMAX Large Scale
RNA Production Systems (Promega, Madison, WI), puriﬁed with
MEGAclear Kit (Ambion) and transfected into Naïve Huh7.5.1 cells
with TransMessenger Transfection Reagent (Qiagen). The transfected
cells were cultured and routinely expanded for 10 days and the
collected virus containing supernatants were pooled and further used
to inoculate naïve Huh7.5.1 cells. This supernatant collection/naïve
cells inoculation process was repeated at lease for 5 cycles with 7 days
each cycle to produce large volume HCVcc stock with relatively high
viral titer. For infections, HCVcc (MOI=1.0) and same amount of
parallel ultra-violet inactivated virus (HCVUV) were used to inoculate
5×106 naïve Huh7.5.1 cells and incubate overnight. Inactivation of
HCV by UV was achieved by exposing virus-containing supernatant in
Petri dish (0.5 cm depth) to 254 nm UV source at 1.8 Jm−2 per second
for 30 min. The infected cells were washed and maintained in fresh
medium for 1, 2, 3 and 4 days, respectively, prior to microarray
analysis.
Microarrays and bioinformatics
Total RNA was isolated from HCV or HCVUV-infected Huh7.5.1
cells with Trizol reagent (Invitrogen). miRNA and mRNA hybridiza-
tion was performed by CapitalBio Corporation (Beijing, China) with
Fig. 4. (A) Signiﬁcantly enriched Gene Ontology terms in the biological process category among differentially expressed genes. (B) Gene and pathway association map of
differentially expressed mRNAs in Huh7.5.1 cells in response to HCV infection.
64 X. Liu et al. / Virology 398 (2010) 57–67the use of mammalian multi-species miRNA microarray version 4.0
(total 1,320 oligo probes recognizing 988 human, 350 rat and 627
mouse mature miRNAs) and 35K Human Genome Array (total 35,035
70-mer oligo probes from Operon, representing 25100 human genes).
miRNA nomenclature in this study is based on miRBase 12.0,
September 2008. A two-channel microarray technology was
employed. For each sample pair, the experiments were done with
two independent hybridizations (Cy3 and Cy5 interchanging label-
ing). Raw data were extracted from the TIFF images using LuxScan 3.0
software (CapitalBio). Hierarchical cluster, gene ontology and path-
way analysis were carried out with Gene Cluster 3.0, Eisen's Treeview
(Stanford University, Palo Alto, CA), as well as Molecule Annotation
System V4.0 (MAS: http://bioinfo.capitalbio.com/mas/).Quantitative real-time RT-PCR (RT-qPCR)
For selected mRNA RT-qPCR, total RNA from the same samples
used in microarray analysis was tested using the ABI Prism 7500
System. Real-time quantiﬁcation was employed using SYBR Green
PCR Master Mix (ABI). PCR primers were designed with AB PRISM
Primer Express 2.0 software. Results are shown as fold change. For
miRNA RT-qPCR, experiments were carried out with the miRNA
Reverse Transcription kit (Applied Biosystems) and miRNA Taqman
Expression Assays (Applied Biosystems) according to manufacture's
instruction. Quantiﬁcation of HCV genomic RNA was performed with
real-time RT-PCR as described in reference (Komurian-Pradel et al.,
2001).
Table 3
Reverse regulatory association of most differentially expressed miRNAs and their
predicted mRNA targets.
miRNA
(or family)
miRNA
change
Target mRNAs Target
change
hsa-miR-15a, 15b Down AFF4, DDX3X, E2F3, ENAH,
PITPNA, KLHL18, KIF21A,
MAPRE1, ACSL1, ARHGAP5,
SPRYD3, CAB39, FAM60A,
KIAA0182, CLCN5, MMD, CDV3,
ARL8B, TMEM87A, SPSB4,
TRAM1, CHORDC1, KIF5B, HIRA,
SUPT16H, HIGD1A
Up
hsa-miR-17,106a, 106b Down AFF4, E2F3, MAPRE1, FAM60A,
PLCB1, M6PR, ARID4B, SOX4,
BAMBI, RNF6, CAMTA2,
SUV420H1, JOSD1, AKAP13,
EIF4G2, SFRS2, PAPOLA,
ADAM9, CRK, MAPK9, MKRN1,
TMEM16F, DNAJB6, LPGAT1,
BTG3, DDX5, DNAJB9,
GRAMD1A, CALD1, NKIRAS1,
JUB, NEDD4L, WAC, SQSTM1
Up
hsa-miR-181a Down AFF4, DDX3X, ENAH, ACSL1,
KIAA0182, PALLD, AP1G1,
G3BP2, ZFP36L1, MAT2A, HRB,
TULP4, TGFBI, PALM2,
IVNS1ABP, RNF6, CAMTA2,
DUSP5, TARDBP, PHF3,
SLC38A2, SFRS7, DOCK7,
KPNB1, RNF34, RAN, GPD1L,
KLF6
Up
hsa-miR-29a, 29b Down AFF4, DDX3X, PITPNA, GPAM,
ZFP36L1, MAT2A, CTNND1,
TDG, RCC2, CHIC2, WDR26,
SUV420H1, JOSD1, AKAP13,
RND3, GNG12, SMARCC1,
COL2A1, SPAST, ARVCF,
MGAT4B, ABCE1, TXNDC4,
DNAJB11, RND1, TNFRSF1A,
TRAF4, TUBB2B
Up
hsa-let-7f Up TRAPPC1, DMD, MYCBP, PIGA,
RNF5, GNG5, IGSF1
Down
hsa-miR-93 Down KLHL18, EPHA2, ARID4B,
BAMBI, RNF6, SUV420H1,
PAPOLA, ADAM9, CRK, MAPK9,
MKRN1, TMEM16F, TARDBP,
MTUS1, YWHAZ, TIPARP
Up
hsa-miR-130a, 130b, 310 Down ACSL1, KIAA0182, CLCN5,
PLCB1, AP1G1, G3BP2,
KIAA0152, ANKRD12, M6PR,
HRB, ARID4B, SOX4, RNF38,
NRBF2, GJA1, RBBP8, CLTC,
SUV420H1, TARDBP, PHF3,
GADD45A, CANX, VPS24
Up
hsa-miR-30a, 30c, 30e Down E2F3, MMD, ARL8B, AFF4,
TMEM87A, SEMA6A, MAT2A,
TDG, TULP4, PALM2, ARID4B,
SOX4, GJA1, KLF10, JOSD1,
PAPOLA, ADAM9, LPGAT1,
NEDD4L, SLC38A2, SFRS7,
SPAST, YWHAZ, AMOTL2, KRAS,
VAPA, EXTL2, GTF2H1, BECN1,
RGS2, LRRC8D, HSPA5, CARS
Up
hsa-miR-24 Down AMOTL2, KIAA0152, CDV3, JUB,
CCT3, DHX30, FST, AARS
Up
hsa-miR-221, 222 Down HRB, CDV3, EIF3S1 Up
Fig. 5. Potential function of differentially expressed miRNAs on HCV life cycle. Eight
synthetic mimics for down-regulated miRNAs, 10 inhibitors for up-regulated miRNAs
and the miRNA mimic or inhibitor controls with no speciﬁc targets were transfected
into naïve Huh7.5.1 cells respectively for determination of the function of selected
miRNAs on HCV entry (A) and HCVcc propagation (C). Similar strategy was employed
on 2−3+ HCV replicon cells harboring genotype 1b full-length genome for
determination of miRNA effects on HCV RNA abundance (B). Two-sample independent
t-test statistics was performed between the individual transfection and correspondent
control. One asterisk (⁎) stands for Pb0.05 and double asterisk (⁎⁎) for Pb0.01.
65X. Liu et al. / Virology 398 (2010) 57–67Immunostaining and confocal microscope
HCV or HCVUV-infected Huh7.5.1 cells were ﬁxed in 2% parafor-
maldehyde (dissolved in PBS, pH7.2) for 10 min at room temperature
(RT). Cells were then permeabilized with 0.2% (v/v) Triton X-100 in
PBS three times (PBST; 10 min each time, RT) and incubated in PBS
(overnight at 4οC) with 1:200 diluted antibody against HCV Core
protein (Afﬁnity BioReagents, Golden, CO). Samples were washed in
66 X. Liu et al. / Virology 398 (2010) 57–67PBS and sequentially incubated with FITC-conjugated secondary
antibody (Santa Cruz) diluted in PBS (1:100). Samples were ﬁnally
washed three times in PBS and mounted on a slide. Nucleus was
visualized with DAPI staining during the second wash. Images were
captured on a Leica TCS SP5 confocal microscope.
Cytotoxicity assays
Naïve Huh7.5.1 cells were plated in quadruplicate in 96-well plates
at a density of 1×104 cells/well 1 day before infection, followed with
HCV or HCVUV infection at MOI=1.0 for various days. Cell viability
and cytotoxicity were examined with MTT assay kit (Promega)
according to manufacture's instruction.
MiRNA transfection
Selected miRNA mimics and inhibitors were synthesized by
Qiagen. MiRNA mimics are chemically synthesized double stranded
miRNAs which mimic naturally occurring miRNAs after transfection
into the cell. miRNA inhibitors are single-stranded, modiﬁed RNAs
which, after transfection, speciﬁcally inhibit miRNA function. These
miRNA mimics and inhibitors were transfected into naïve Huh7.5.1
cells at a ﬁnal concentration of 50 nM with HiPerFect Transfection
Reagent according to Qiagen recommended protocol. Twenty-four
hours post-transfection, the cells were spin infected with lentivirus
particles pseudotyped with HCV E1 and E2 glycoproteins (HCVpp) to
evaluate the effects of miRNAs on HCV entry. For 2−3+ replicon cells,
total RNAwas isolated 24 h post-transfection with miRNAmimics and
inhibitors for HCV replication quantiﬁcation by real-time RT-PCR. For
the assessment of miRNA effects on HCVcc infection, naïve Huh7.5.1
cells were infected with HCVcc at lowMOI (=0.1) on the ﬁrst day and
followed with miRNA mimics and inhibitors transfection on the
second day. HCV genome quantiﬁcation by qRT-PCR was performed
on the fourth day post-infection. All experiments were carried out at
triplicates. To conﬁrm the efﬁciency of transfection, the same amount
of Cy3-labelled negative control (Ambion) was also transfected and
followed by ﬂuorescent microscope observation.
Production of HCVpp and the entry assay
HCVpp packaging was performed as described elsewhere (Yang
et al., 2008b). Brieﬂy, HEK293T cells were seeded 1 day before
transfection at 2.5×106 cells in a 10-cm plate. Cells were transfected
using TransMax Transfection Reagent (Giantagen, Beijing, China). The
transfecting DNA mixture (1 ml) was composed of 15 μg of pNL-4.3-
Luc-E−R−, either 15 μg of phCMV-HCV E1E2 (genotype 1a) or 3 μg of
pHEF-VSV-G. Culture supernatants containing HCVpp or VSVpp
(lentivirus particles pseudotyped with VSV-G glycoprotein) were
collected at 48, 60 and 72 h post-transfection and ﬁltered through
0.22-μm syringe ﬁlter. For virus entry assay, Huh7.5.1 cells were
seeded in a 24-well plate at the density of 1×105/well on the day
before transduction. On the following day, the cells will be supple-
mentedwith 500 μl of HCVpp or VSVpp containing supernatants in the
presence of 8 μg/ml of polybrene and 5 μl of 2 M HEPES (pH 7.55) and
spin infected for 1.5 h in a table-top centrifuge (2500 rpm, 30 °C) and
followed by another 1.5 h incubation in a CO2 cell incubator. Cells were
lysed at 48 h post-spin infection and assayed with Luciferase Assay
System (Promega) in a Modulus Microplate Luminometer (Turner
BioSystems). All experiments were performed in triplicates. To obtain
the speciﬁc HCV envelope proteins (E1/E2) mediated cell entry,
normalization of HCV entry assaywas carried out by dividing of HCVpp
relative luciferase units (RLU) by relative VSVpp variation folds.
Acknowledgments
This work was supported by Chinese National Key Project
(2008ZX10002-014, 2009ZX10603), National Natural Science Founda-tion of China (30970156), and an intramural grant from the Institute of
PathogenBiology, ChineseAcademyofMedical Sciences (2008IPB107)
to W. Y.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.virol.2009.11.036.
References
Amemiya, F., Maekawa, S., Itakura, Y., Kanayama, A., Matsui, A., Takano, S., Yamaguchi,
T., Itakura, J., Kitamura, T., Inoue, T., Sakamoto, M., Yamauchi, K., Okada, S.,
Yamashita, A., Sakamoto, N., Itoh, M., Enomoto, N., 2008. Targeting lipid
metabolism in the treatment of hepatitis C virus infection. J. Infect. Dis. 197,
361–370.
Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116,
281–297.
Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., D'Urso, L.,
Pagliuca, A., Biffoni, M., Labbaye, C., Bartucci, M., Muto, G., Peschle, C., De Maria, R.,
2008. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple
oncogenic activities. Nat. Med. 14, 1271–1277.
Cai, Z., Zhang, C., Chang, K.S., Jiang, J., Ahn, B.C., Wakita, T., Liang, T.J., Luo, G., 2005.
Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-
transfected human hepatoma cells. J. Virol. 79, 13963–13973.
Carraro, G., El-Hashash, A., Guidolin, D., Tiozzo, C., Turcatel, G., Young, B.M., De Langhe,
S.P., Bellusci, S., Shi, W., Parnigotto, P.P., Warburton, D., 2009. miR-17 family of
microRNAs controls FGF10-mediated embryonic lung epithelial branching mor-
phogenesis through MAPK14 and STAT3 regulation of E-cadherin distribution.
Dev. Biol. 333, 238–250.
Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., 1989.
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis
genome. Science 244, 359–362.
Cimmino, A., Calin, G.A., Fabbri, M., Iorio, M.V., Ferracin, M., Shimizu, M., Wojcik, S.E.,
Aqeilan, R.I., Zupo, S., Dono, M., Rassenti, L., Alder, H., Volinia, S., Liu, C.G., Kipps, T.J.,
Negrini, M., Croce, C.M., 2005. miR-15 and miR-16 induce apoptosis by targeting
BCL2. Proc. Natl. Acad. Sci. U.S.A. 102, 13944–13949.
Evans, M.J., von Hahn, T., Tscherne, D.M., Syder, A.J., Panis, M., Wolk, B., Hatziioannou, T.,
McKeating, J.A., Bieniasz, P.D., Rice, C.M., 2007. Claudin-1 is a hepatitis C virus co-
receptor required for a late step in entry. Nature 446, 801–805.
Guo, C.J., Pan, Q., Li, D.G., Sun, H., Liu, B.W., 2009. miR-15b and miR-16 are implicated in
activation of the rat hepatic stellate cell: an essential role for apoptosis. J. Hepatol.
50, 766–778.
Hon, L.S., Zhang, Z., 2007. The roles of binding site arrangement and combinatorial
targeting in microRNA repression of gene expression. Genome Biol. 8, R166.
Johansson, D.X., Voisset, C., Tarr, A.W., Aung, M., Ball, J.K., Dubuisson, J., Persson, M.A.,
2007. Human combinatorial libraries yield rare antibodies that broadly neutralize
hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 104, 16269–16274.
Jopling, C.L., Yi, M., Lancaster, A.M., Lemon, S.M., Sarnow, P., 2005. Modulation of
hepatitis C virus RNA abundance by a liver-speciﬁc microRNA. Science 309,
1577–1581.
Komurian-Pradel, F., Paranhos-Baccala, G., Sodoyer, M., Chevallier, P., Mandrand, B.,
Lotteau, V., Andre, P., 2001. Quantitation of HCV RNA using real-time PCR and
ﬂuorimetry. J. Virol. Methods 95, 111–119.
Li, Y., Tan, W., Neo, T.W., Aung, M.O., Wasser, S., Lim, S.G., Tan, T.M., 2009. Role of the
miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 100,
1234–1242.
Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C.,
Maruyama, T., Hynes, R.O., Burton, D.R., McKeating, J.A., Rice, C.M., 2005. Complete
replication of hepatitis C virus in cell culture. Science 309, 623–626.
Liu, S., Yang, W., Shen, L., Turner, J.R., Coyne, C.B., Wang, T., 2009. Tight junction proteins
claudin-1 and occludin control hepatitis C virus entry and are downregulated
during infection to prevent superinfection. J. Virol. 83, 2011–2014.
Marcucci, G., Radmacher, M.D., Maharry, K., Mrozek, K., Ruppert, A.S., Paschka, P.,
Vukosavljevic, T., Whitman, S.P., Baldus, C.D., Langer, C., Liu, C.G., Carroll, A.J.,
Powell, B.L., Garzon, R., Croce, C.M., Kolitz, J.E., Caligiuri, M.A., Larson, R.A.,
Bloomﬁeld, C.D., 2008. MicroRNA expression in cytogenetically normal acute
myeloid leukemia. N. Engl. J. Med. 358, 1919–1928.
Marsit, C.J., Eddy, K., Kelsey, K.T., 2006. MicroRNA responses to cellular stress. Cancer
Res. 66, 10843–10848.
Martello, G., Zacchigna, L., Inui, M., Montagner, M., Adorno, M., Mamidi, A., Morsut, L.,
Soligo, S., Tran, U., Dupont, S., Cordenonsi, M., Wessely, O., Piccolo, S., 2007.
MicroRNA control of Nodal signalling. Nature 449, 183–188.
Murakami, Y., Aly, H.H., Tajima, A., Inoue, I., Shimotohno, K., 2009. Regulation of the
hepatitis C virus genome replication by miR-199a. J. Hepatol. 50, 453–460.
Nathans, R., Chu, C.Y., Serquina, A.K., Lu, C.C., Cao, H., Rana, T.M., 2009. Cellular
microRNA and P bodies modulate host-HIV-1 interactions. Mol. Cell 34,
696–709.
Park, S.Y., Lee, J.H., Ha, M., Nam, J.W., Kim, V.N., 2009. miR-29 miRNAs activate p53 by
targeting p85 alpha and CDC42. Nat. Struct. Mol. Biol. 16, 23–29.
Pedersen, I.M., Cheng, G., Wieland, S., Volinia, S., Croce, C.M., Chisari, F.V., David, M.,
2007. Interferon modulation of cellular microRNAs as an antiviral mechanism.
Nature 449, 919–922.
67X. Liu et al. / Virology 398 (2010) 57–67Peng, X., Li, Y., Walters, K.A., Rosenzweig, E.R., Lederer, S.L., Aicher, L.D., Proll, S., Katze,
M.G., 2009. Computational identiﬁcation of hepatitis C virus associated microRNA-
mRNA regulatory modules in human livers. BMC Genomics 10, 373.
Petrocca, F., Vecchione, A., Croce, C.M., 2008. Emerging role of miR-106b-25/miR-17-92
clusters in the control of transforming growth factor beta signaling. Cancer Res. 68,
8191–8194.
Raychaudhuri, S., Fontanes, V., Barat, B., Dasgupta, A., 2009. Activation of ribosomal RNA
transcription by hepatitis C virus involves upstream binding factor phosphorylation
via induction of cyclin D1. Cancer Res. 69, 2057–2064.
Rogler, C.E., Levoci, L., Ader, T., Massimi, A., Tchaikovskaya, T., Norel, R., Rogler, L.E.,
2009. MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/
bone morphogenetic protein signaling and liver stem cell differentiation by
targeting Smads. Hepatology 50, 575–584.
Sarasin-Filipowicz, M., Krol, J., Markiewicz, I., Heim, M.H., Filipowicz, W., 2009.
Decreased levels of microRNA miR-122 in individuals with hepatitis C responding
poorly to interferon therapy. Nat. Med. 15, 31–33.
Shepard, C.W., Finelli, L., Alter, M.J., 2005. Global epidemiology of hepatitis C virus
infection. Lancet Infect. Dis. 5, 558–567.
Timpe, J.M., Stamataki, Z., Jennings, A., Hu, K., Farquhar, M.J., Harris, H.J., Schwarz, A.,
Desombere, I., Roels, G.L., Balfe, P., McKeating, J.A., 2008. Hepatitis C virus cell-cell
transmission in hepatoma cells in the presence of neutralizing antibodies.
Hepatology 47, 17–24.
Ura, S., Honda, M., Yamashita, T., Ueda, T., Takatori, H., Nishino, R., Sunakozaka, H., Sakai,
Y., Horimoto, K., Kaneko, S., 2009. Differential microRNA expression between
hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma.
Hepatology 49, 1098–1112.
Uzri, D., Gehrke, L., 2009. Nucleotide sequences and modiﬁcations that determine RIG-
I/RNA binding and signaling activities. J. Virol. 83, 4174–4184.Varnholt, H., Drebber, U., Schulze, F., Wedemeyer, I., Schirmacher, P., Dienes, H.P.,
Odenthal, M., 2008. MicroRNA gene expression proﬁle of hepatitis C virus-
associated hepatocellular carcinoma. Hepatology 47, 1223–1232.
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K.,
Habermann, A., Krausslich, H.G., Mizokami, M., Bartenschlager, R., Liang, T.J., 2005.
Production of infectious hepatitis C virus in tissue culture from a cloned viral
genome. Nat. Med. 11, 791–796.
Walters, K.A., Syder, A.J., Lederer, S.L., Diamond, D.L., Paeper, B., Rice, C.M., Katze, M.G.,
2009. Genomic analysis reveals a potential role for cell cycle perturbation in HCV-
mediated apoptosis of cultured hepatocytes. PLoS Pathog. 5, e1000269.
Wang, H., Garzon, R., Sun, H., Ladner, K.J., Singh, R., Dahlman, J., Cheng, A., Hall, B.M.,
Qualman, S.J., Chandler, D.S., Croce, C.M., Guttridge, D.C., 2008. NF-kappaB-YY1-
miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer
Cell 14, 369–381.
Yang, W., Hood, B.L., Chadwick, S.L., Liu, S., Watkins, S.C., Luo, G., Conrads, T.P., Wang, T.,
2008a. Fatty acid synthase is up-regulated during hepatitis C virus infection and
regulates hepatitis C virus entry and production. Hepatology 48, 1396–1403.
Yang, W., Qiu, C., Biswas, N., Jin, J., Watkins, S.C., Montelaro, R.C., Coyne, C.B., Wang, T.,
2008b. Correlation of the tight junction-like distribution of Claudin-1 to the cellular
tropism of hepatitis C virus. J. Biol. Chem. 283, 8643–8653.
Ye, L., Wang, X., Wang, S., Wang, Y., Song, L., Hou,W., Zhou, L., Li, H., Ho,W., 2009. CD56+ T
cells inhibit hepatitis Cvirus replication inhumanhepatocytes.Hepatology49, 753–762.
Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D.R., Wieland, S.F.,
Uprichard, S.L., Wakita, T., Chisari, F.V., 2005. Robust hepatitis C virus infection in
vitro. Proc. Natl. Acad. Sci. U.S.A. 102, 9294–9299.
Zhu, H., Dong, H., Eksioglu, E., Hemming, A., Cao, M., Crawford, J.M., Nelson, D.R., Liu, C.,
2007. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line
through antiviral defense system. Gastroenterology 133, 1649–1659.
